Tradestie Institutional Equity Comparison Engine

VIVS vs OBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OBIO Overall Edge

OBIO Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VIVS trades at N/M Forward P/E with -10117.0% operating margin (-51.4% YoY revenue) versus OBIO at N/M Forward P/E and -195.4% operating margin (-89.4% YoY). In options structure, VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against OBIO sits in BREAKOUT (21st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
VIVS N/M vs OBIO N/M Fwd P/E
Growth & Margin Winner OBIO
Op Margin -10117.0% vs -195.4% ยท YoY -51.4% vs -89.4%
Momentum & Technical Winner OBIO
1Y -87.0% vs +65.5% ยท 52W Pos 5% vs 81%
Options & Structure Winner OBIO
BREAKDOWN (N/A IV) vs BREAKOUT (21st %ile IV)
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
1M Return +64.69%
1Y Return -86.99%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.00
-6.17% 1D
Market Cap $587.1M
1M Return +20.59%
1Y Return +65.48%
Forward P/E N/M
Unified AI Score
37.8 / 100 SELL
Tech 50.0 Fund 36.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VIVS -86.99% OBIO +65.48% Spread: +152.47 pp (OBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period VIVS Revenue OBIO Revenue VIVS Op. Margin OBIO Op. Margin Margin Edge
FY2018 $0M N/A -766.3% N/A VIVS
FY2019 $0M N/A -882.4% N/A VIVS
FY2020 $0M N/A -977.9% N/A VIVS
FY2022 $0M $0M -765.3% -924.3% VIVS
FY2023 $0M $0M -4792.2% -1866.2% OBIO
FY2024 $0M $0M -13840.4% -2437.5% OBIO
FY2025 $0M $30M -8761.1% -154.7% OBIO
FY2026 $0M N/A -8768.7% N/A VIVS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VIVS (2) vs OBIO (6)
Institutional Metric VIVS OBIO Criterion Row Winner
Market Capitalization Scale $2.4M $587.1M Larger Scale OBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -51.4% -89.4% Higher Growth VIVS
Operating Margin (TTM) Profitability -10117.0% -195.4% Higher Margin OBIO
Net Profit Margin Profitability 0.0% -182.5% Higher Margin VIVS
Return on Equity (ROE) Capital Efficiency -343.1% -182.3% Higher ROE OBIO
52-Week Range Position Momentum 5% ($0โ€“$3) 81% ($3โ€“$8) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 0.83ฮฒ ยท 480% Vol 1.14ฮฒ ยท 86% Vol Lower Realized Risk OBIO
Unified Institutional Score Composite Signal 36.8 / 100 (SELL) 37.8 / 100 (SELL) Higher Composite OBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VIVS vs OBIO Buy Guide
VIVS BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VIVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OBIO BREAKOUT
35d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 21st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VIVS nor OBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.